Evidence map›Paper›PMID 41369255›Full record

ArticlemBio2025

Anjali Anil, Rezia Era D Braza, Bessie Liu, Valerie Altouma, Clement Adedeji, Ananyaa Welling, Alysha L Ellison, Megan H Check, Irnov Irnov, Rachel Prescott and 2 more

Abstract read
In one paragraph

Article in mBio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. bioRxiv : the preprint server for biology · 2025
    Article
4 · The record

Corrections and comments

  • Update of
    2025
5 · Who and what money

Authors and funding

12 authors.

Anjali Anil *W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Rezia Era D Braza *W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Bessie LiuW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Valerie AltoumaW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Clement AdedejiW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Ananyaa WellingW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Alysha L EllisonW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Megan H CheckW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Irnov IrnovDepartment of Microbiology, New York University Grossman School of Medicine, New York, New York, USA.
Rachel PrescottDepartment of Host-Microbe Interactions, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
Victor J TorresDepartment of Microbiology, New York University Grossman School of Medicine, New York, New York, USA.ORCID 0000-0002-7126-0489
Kimberly M DavisW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.ORCID 0000-0003-1870-3137

Funding

Mechanistic Studies Of The Staphylococcus aureus LukAB CytotoxinR01AI099394 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Victor J. Torres · 2013 to 2026
$6.1M
Contribution of LukED to Staphylococcus aureus pathobiologyR01AI105129 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI TORRES, VICTOR J. · 2014 to 2023
$4.9M
S. aureus virulence factor expression during kidney abscess formationR21AI159473 · NIAID · JOHNS HOPKINS UNIVERSITY · PI DAVIS, KIM · 2022 to 2023
$450k
NIAID NIH HHS R01 AI099394NIAID NIH HHS R01 AI105129NIAID NIH HHS R21 AI159473
6 · The paper itself

Abstract

Virulence factors are required for bacterial pathogens to establish infection; however, their expression can be energetically costly and must be tightly controlled to avoid fitness costs. Expression can be controlled at specific stages during infection (temporal regulation) or expressed by small subsets of the bacterial population (spatial regulation). There has been a great deal of interest in developing virulence factor-targeting strategies to combat IMPORTANCE: Infections with

Indexed as

AbscessBacterial ProteinsStaphylococcal InfectionsStaphylococcus aureusAnimalsDisease Models, AnimalGene Expression Regulation, BacterialGenes, ReporterKidneyMiceProtein KinasesTrans-ActivatorsVirulence FactorsAgr protein, Staphylococcus aureusBacterial ProteinsProtein KinasesSaeS protein, Staphylococcus aureusTrans-ActivatorsVirulence Factorsheterogeneitykidney abscessStaphylococcus aureusvirulence factors

Identifiers

PMID41369255
PMCPMC12691657

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.